3 recruiting, 3 terminated, 2 completed, 1 active not recruiting. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 2, Recruiting 2, Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Terminated 3, Recruiting 2 |
Follow Metastatic Leiomyosarcoma: new trials by email Literature Review of Metastatic Leiomyosarcoma trials Research Report on Metastatic Leiomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma Abemaciclib, Biopsy Procedure, Biospecimen Collection - Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2026-03-18 | 2026-10-21 |
| XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma Biospecimen Collection, Computed Tomography, Echocardiography - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Recruiting | Northwestern University | 73 | 2024-09-19 | 2026-10-13 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-10-28 |
| Niraparib for the Treatment of Leiomyosarcoma Niraparib Tosylate Monohydrate - Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma | Phase 2 | Withdrawn | David Liebner, MD | 2023-12-01 | 2023-09-18 | |
| Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Cabozantinib, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 96 | 2020-01-14 | 2026-05-01 |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Itacitinib, Laboratory Biomarker Analysis - Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 27 | 2019-09-30 | 2024-05-08 |
| Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Avelumab, Trabectedin - Metastatic Leiomyosarcoma, Metastatic Liposarcoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 35 | 2017-09-28 | 2022-04-29 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
| SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Mocetinostat, Gemcitabine - Metastatic Leiomyosarcoma | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 20 | 2015-11-12 | 2019-01-29 |
| Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2015-05-19 | 2025-02-25 |
Leiomyosarcoma (10) · Sarcoma (4) · Sarcoma, Synovial (4) · Histiocytoma, Malignant Fibrous (3) · Liposarcoma (3) · Dermatofibrosarcoma (2) · Bone Neoplasms (1) · Chondrosarcoma (1) · Liposarcoma, Myxoid (1) · Neurofibrosarcoma (1) · Osteosarcoma (1) · Sarcoma, Ewing (1)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Connective and Soft Tissue (10) · Neoplasms, Muscle Tissue (10) · Sarcoma (6) · Neoplasms, Adipose Tissue (4) · Neoplasms, Connective Tissue (4) · Histiocytoma (3) · Neoplasms, Fibrous Tissue (3) · Fibrosarcoma (2) · Bone Diseases (1) · Liposarcoma (1) · Musculoskeletal Diseases (1) · Neoplasms by Site (1) · Neoplasms, Bone Tissue (1)
Specimen Handling (3) · Biopsy (2) · Gemcitabine (2) · CTLA-4 Antigen (1) · Docetaxel (1) · Doxorubicin (1) · INCB039110 (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Temozolomide (1) · Trabectedin (1) · abemaciclib (1) · avelumab (1) · baricitinib (1)
National Cancer Institute (NCI) (4) · Fred Hutchinson Cancer Center (2) · City of Hope Medical Center (1) · David Liebner, MD (1) · Northwestern University (1) · Sarcoma Alliance for Research through Collaboration (1)
United States (9)
Candace L Haddox (1) · David Liebner, MD (1) · Edwin Choy, MD, PhD (1) · Elise F Nassif (1) · Janet Yoon, MD (1) · Lee Cranmer (1) · Pedro Hermida de Viveiros, MD (1) · Seth Pollack (1) · Shreyas Patel, MD (1) · Suzanne George (1) · William D Tap (1)
P30CA060553 (2), UM1CA186709 (2), P30CA015704 (1), U10CA180821 (1), UM1CA186688 (1)